Cargando…

Severe delayed pulmonary toxicity following PD‐L1–specific CAR‐T cell therapy for non‐small cell lung cancer

OBJECTIVES: This phase I study aimed to evaluate the antitumor effect and safety of programmed death‐ligand‐1 (PD‐L1)–targeting autologous chimeric antigen receptor T (CAR‐T) cells for patients with non‐small cell lung cancer (NSCLC). METHODS: Programmed death‐ligand‐1–specific CAR‐T cells were gene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Heping, Ma, Yuxiang, Yang, Chaopin, Xia, Shangzhou, Pan, Qiuzhong, Zhao, Hongyun, Fang, Wenfeng, Chen, Xi, Zhang, Yang, Zou, Benyan, Li, Qiuyuan, Wan, Yang, Chen, Hao, Tang, Yan, Zhao, Jingjing, Weng, Desheng, Xia, Liming, Zhang, Li, Xia, Jianchuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546952/ https://www.ncbi.nlm.nih.gov/pubmed/33072320 http://dx.doi.org/10.1002/cti2.1154

Ejemplares similares

Adjuvant alternative cytokine-induced killer cell combined with natural killer cell immunotherapy improves the prognosis of post-mastectomy breast cancer
por: Yang, Xinyi, et al.
Publicado: (2022)

Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma
por: Yang, Chaopin, et al.
Publicado: (2023)

Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRβ complex in hepatocellular carcinoma
por: Yang, Jieying, et al.
Publicado: (2023)

SPC25 promotes proliferation and stemness of hepatocellular carcinoma cells via the DNA-PK/AKT/Notch1 signaling pathway
por: Yang, Jieying, et al.
Publicado: (2022)

Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin
por: Sun, Fengze, et al.
Publicado: (2021)

CMTM6 inhibits tumor growth and reverses chemoresistance by preventing ubiquitination of p21 in hepatocellular carcinoma
por: Huang, Yue, et al.
Publicado: (2022)

CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype
por: Li, Han, et al.
Publicado: (2022)

Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy
por: Ali, Wael Abdullah Sultan, et al.
Publicado: (2021)

The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study
por: Song, Meng‐Jia, et al.
Publicado: (2021)

Large-scale analyses identify a cluster of novel long noncoding RNAs as potential competitive endogenous RNAs in progression of hepatocellular carcinoma
por: Song, Mengjia, et al.
Publicado: (2019)

BCL2L10/BECN1 modulates hepatoma cells autophagy by regulating PI3K/AKT signaling pathway
por: He, Jiafa, et al.
Publicado: (2019)

OTUD4-mediated GSDME deubiquitination enhances radiosensitivity in nasopharyngeal carcinoma by inducing pyroptosis
por: Di, Muping, et al.
Publicado: (2022)

BMP9‐induced vascular normalisation improves the efficacy of immunotherapy against hepatitis B virus‐associated hepatocellular carcinoma
por: Han, Yulong, et al.
Publicado: (2023)

Alarmin IL-33 orchestrates antitumoral T cell responses to enhance sensitivity to 5-fluorouracil in colorectal cancer
por: Song, Mengjia, et al.
Publicado: (2023)

Influence of obesity on in-hospital and postoperative outcomes of hepatic resection for malignancy: a 10-year retrospective analysis from the US National Inpatient Sample
por: He, Jiafa, et al.
Publicado: (2019)

SKA1 overexpression is associated with poor prognosis in hepatocellular carcinoma
por: Chen, Yibing, et al.
Publicado: (2018)

Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2021)

Synergistic killing effects of PD-L1-CAR T cells and colorectal cancer stem cell-dendritic cell vaccine-sensitized T cells in ALDH1-positive colorectal cancer stem cells
por: Liu, Liu, et al.
Publicado: (2021)

Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
por: Sheng, Jin, et al.
Publicado: (2016)

Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non-small cell lung cancer
por: Sheng, Jin, et al.
Publicado: (2017)

Combinatorial assessment of ctDNA release and mutational burden predicts anti‐PD(L)1 therapy outcome in nonsmall‐cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2020)

Galectin-3 favours tumour metastasis via the activation of β-catenin signalling in hepatocellular carcinoma
por: Song, Mengjia, et al.
Publicado: (2020)

Erratum: Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
por: Sheng, Jin, et al.
Publicado: (2016)

Pretreatment Serum Lactate Dehydrogenase and Metastases Numbers as Potential Determinants of Anti-PD-1 Therapy Outcome in Nasopharyngeal Carcinoma
por: Ali, Wael A. S., et al.
Publicado: (2023)

Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer
por: Ao, Xiang, et al.
Publicado: (2019)

Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy
por: He, Li-na, et al.
Publicado: (2021)

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition
por: Zhang, Xuanye, et al.
Publicado: (2019)

The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis
por: Zhang, Tengfei, et al.
Publicado: (2016)

A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis
por: Ma, Qizhi, et al.
Publicado: (2022)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023)

Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity
por: Shi, Xiaojuan, et al.
Publicado: (2019)

Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
por: Wang, Zhenguang, et al.
Publicado: (2021)

Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung Cancer
por: Xia, Liliang, et al.
Publicado: (2021)

Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma
por: Wei, Shuping, et al.
Publicado: (2019)

Optimization of metabolism to improve efficacy during CAR-T cell manufacturing
por: Zhang, Meng, et al.
Publicado: (2021)

Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer
por: Zhao, Shen, et al.
Publicado: (2021)

Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell
por: Yang, Chaopin, et al.
Publicado: (2020)

A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy
por: Li, Tongjuan, et al.
Publicado: (2019)

HIV-1-Specific CAR-T Cells With Cell-Intrinsic PD-1 Checkpoint Blockade Enhance Anti-HIV Efficacy in vivo
por: Jiang, Zhengtao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sq4hq9keseormb7qeccobt851b